Ascendis Pharma A/S (NASDAQ:ASND) Trading 4.3% Higher After Analyst Upgrade

Ascendis Pharma A/S (NASDAQ:ASND)’s stock price was up 4.3% during trading on Thursday after StockNews.com upgraded the stock from a sell rating to a hold rating. The company traded as high as $126.94 and last traded at $124.66. Approximately 64,418 shares changed hands during trading, a decline of 83% from the average daily volume of 387,802 shares. The stock had previously closed at $119.50.

ASND has been the topic of a number of other reports. Jefferies Financial Group lifted their price objective on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th. Citigroup dropped their price objective on Ascendis Pharma A/S from $193.00 to $178.00 and set a “buy” rating for the company in a research report on Wednesday. Bank of America boosted their target price on Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday. The Goldman Sachs Group raised their price target on shares of Ascendis Pharma A/S from $170.00 to $195.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th. Finally, Oppenheimer upgraded shares of Ascendis Pharma A/S from a “market perform” rating to an “outperform” rating and set a $180.00 price objective for the company in a research report on Thursday. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $187.08.

Institutional Investors Weigh In On Ascendis Pharma A/S

Institutional investors have recently made changes to their positions in the stock. Vestal Point Capital LP bought a new stake in Ascendis Pharma A/S in the fourth quarter valued at approximately $78,719,000. GSA Capital Partners LLP acquired a new stake in shares of Ascendis Pharma A/S during the first quarter worth $992,000. Price T Rowe Associates Inc. MD raised its stake in Ascendis Pharma A/S by 23.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after buying an additional 336,976 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in Ascendis Pharma A/S in the fourth quarter valued at $5,779,000. Finally, Perceptive Advisors LLC acquired a new position in Ascendis Pharma A/S in the fourth quarter valued at $16,648,000.

Ascendis Pharma A/S Stock Up 0.1 %

The stock’s 50-day simple moving average is $134.38 and its 200 day simple moving average is $138.20. The firm has a market cap of $6.94 billion, a P/E ratio of -12.40 and a beta of 0.63.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.